ELV Stock Analysis — Elevance Health
Sector: Healthcare
AI Verdict
ELV trades at 13.5x next year's earnings with just 5.9% EPS growth expected, so you're getting a discount for a sticky business model, but the extreme RSI of 84.8 means the stock is priced for a reversal unless growth surprises to the upside.
Competitive Moat
Elevance Health operates as a national health insurer with scale-driven bargaining power over providers and a sticky membership base due to employer and government contracts. Its defensibility comes from regulatory complexity and entrenched relationships with large corporate and public sector clients.
Summary
ELV is flashing an extreme technical signal with an RSI of 84.8, despite a -9.65% one-year return and only modest earnings growth ahead.
Where It Stands
ELV trades at 13.5x forward earnings versus the healthcare sector median of 22x, but its RSI of 84.8 signals extreme overbought conditions even as the stock lags with a -9.65% one-year return.
Key Metrics
- RSI: 84.8 — Overbought
- Trailing P/E: 14.3x
- Forward P/E: 13.5x
- PEG Ratio: 2.41
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- Market Cap: $81.0B
- Dividend Yield: 0.02%
- 1-Year Return: -9.65%
- 52-Week High: $424.24
- 52-Week Low: $273.71
Analyst Consensus
16 Buy · 13 Hold · 0 Sell (29 analysts)
Bull Case
With a forward P/E of 13.5x and expected EPS growth of 5.9%, ELV is priced below sector norms, offering a rare discount for a national insurer with scale advantages.
Bear Case
If ELV's P/E reverts from 14.3x to 12x in line with a cooling RSI, that would erase roughly 16% of its market value even before factoring in tepid 5.9% EPS growth.
Catalyst to Watch
Watch for regulatory changes or contract wins that could accelerate EPS growth above the current 5.9% forecast and justify the current valuation.